7 Or 8 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.7)
-
Patent number: 11826431Abstract: The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.Type: GrantFiled: August 24, 2021Date of Patent: November 28, 2023Assignee: FUDAN UNIVERSITYInventors: Gang Wei, Kuan Jiang, Weiyue Lu, Chang Liu, Lingyu Tai, Xin Gao
-
Patent number: 11576857Abstract: Methods and compositions for delivering medicine and other substances to the brain and the body via the cribriform plate using foamable compositions are described. Methods and compositions for improving nasal hygiene and moisturizing the nasal cavity using foamable compositions are also described.Type: GrantFiled: December 18, 2019Date of Patent: February 14, 2023Inventor: Sanjay Gupta
-
Patent number: 11352391Abstract: Eleven synthetic neurokinin A peptide analogs are provided as therapeutic compounds for inducing voluntary “on-demand” voiding of urine and feces in mammals who cannot void without external invasion of the bladder and bowel or those who void involuntarily (i.e., those having urinary and/or fecal incontinence). This control over when and where individuals void offers a drastic improvement in quality of life.Type: GrantFiled: March 21, 2018Date of Patent: June 7, 2022Assignee: DIGNIFY THERAPEUTICS, LLCInventors: Daniel Joseph Ricca, Edward C. Burgard
-
Patent number: 10683326Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.Type: GrantFiled: March 10, 2017Date of Patent: June 16, 2020Assignee: Stealth BioTherapeutics Corp.Inventors: Scott M. Duncan, Martin P. Redmon
-
Patent number: 10631616Abstract: A sheet pack comprising an absorbent layer impregnated with a treatment composition containing at least one ingredient that when topically applied to skin stimulates a gene that is variably expressed over a 24 hour period in native untreated skin cells; the sheet pack contained in a package with user instructions to topically apply the sheet pack to the skin at a time when the gene that is stimulated by the ingredient is being maximally expressed in native untreated skin cells; and methods for treating skin and methods for making a sheet pack.Type: GrantFiled: November 15, 2017Date of Patent: April 28, 2020Assignee: ELC Management LLCInventors: Anne Carullo, Jennifer Palmer Quintano, Joyce Kassouf, Nadine Pernodet, Donald Collins, Dawn Layman, Allan Hafkin, Osvaldo Fontanet
-
Patent number: 10183055Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.Type: GrantFiled: January 9, 2017Date of Patent: January 22, 2019Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Meredith Hay, John Konhilas, Robin L. Polt, Todd Vanderah, Brittany Forte, Tally Milnes, Evan Jones, Lajos Szabo
-
Patent number: 10028999Abstract: The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C?-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.Type: GrantFiled: May 11, 2015Date of Patent: July 24, 2018Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Joab Chapman, Efrat Shavit-Stein
-
Patent number: 10022314Abstract: Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH2. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage.Type: GrantFiled: November 30, 2016Date of Patent: July 17, 2018Assignee: ELC MANAGEMENT LLCInventors: Nadine Pernodet, Kelly Dong, Edward Pelle
-
Patent number: 9987330Abstract: Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.Type: GrantFiled: December 4, 2014Date of Patent: June 5, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark A. Hoon, Santosh K. Mishra
-
Patent number: 9914775Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.Type: GrantFiled: August 21, 2014Date of Patent: March 13, 2018Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
-
Patent number: 9279807Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.Type: GrantFiled: August 22, 2011Date of Patent: March 8, 2016Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMOREInventors: Alessio Fasano, Blake Paterson
-
Patent number: 9220744Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: GrantFiled: January 11, 2014Date of Patent: December 29, 2015Assignee: Lumen Therapeutics, LLCInventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Patent number: 9187526Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.Type: GrantFiled: February 18, 2014Date of Patent: November 17, 2015Inventors: Robert J. Hickey, Linda H. Malkas
-
Publication number: 20150148295Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.Type: ApplicationFiled: February 9, 2015Publication date: May 28, 2015Inventors: Kevin Burton, Torsten Woehr, Thomas R. Tice, Mimoun Ayoub
-
Publication number: 20150140060Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: ApplicationFiled: November 14, 2014Publication date: May 21, 2015Inventor: Gautam GHATNEKAR
-
Publication number: 20150140046Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.Type: ApplicationFiled: April 12, 2013Publication date: May 21, 2015Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
-
Publication number: 20150140093Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.Type: ApplicationFiled: November 6, 2014Publication date: May 21, 2015Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
-
Patent number: 9034824Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: July 3, 2014Date of Patent: May 19, 2015Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Patent number: 9029327Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (Formula?I) (SEQ?ID?NO:?1) (X1)m(X2)n(X3)oX4X5HPX6, for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).Type: GrantFiled: July 23, 2010Date of Patent: May 12, 2015Assignee: Affiris AGInventors: Günther Staffler, Petra Lührs, Andreas Mairhofer, Frank Mattner, Walter Schmidt, Andrea Dolischka
-
Publication number: 20150126457Abstract: A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactic ally as soon as possible post-injury in treating neuronal injury.Type: ApplicationFiled: April 17, 2013Publication date: May 7, 2015Inventors: Dennis J. Goebel, John Marshall
-
Publication number: 20150125522Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.Type: ApplicationFiled: September 12, 2014Publication date: May 7, 2015Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Publication number: 20150125392Abstract: AV?6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AV?6 mediated diseases.Type: ApplicationFiled: December 11, 2014Publication date: May 7, 2015Inventors: Mark J. Howard, Danielle Dicara, John Marshall
-
Publication number: 20150118315Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.Type: ApplicationFiled: June 13, 2012Publication date: April 30, 2015Applicant: Stealth Peptides International, Inc.Inventor: D. Travis Wilson
-
Publication number: 20150119341Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: ApplicationFiled: December 30, 2014Publication date: April 30, 2015Inventors: Wei Yang, Yi-Qun Shi
-
Publication number: 20150119340Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
-
Publication number: 20150111837Abstract: The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: A-Thr-Lys-Pro-B-C-D-X, where: A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gin, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg, Thr-Lys-Pro-Arg-Gly.Type: ApplicationFiled: May 28, 2013Publication date: April 23, 2015Applicant: "IVIX" Ltd.Inventors: Nikolay Fedorovich Myasoedov, Lyudmila Alexandrovna Andreeva, Dmitriy Viktorovich Golikov
-
Patent number: 9012603Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: December 18, 2009Date of Patent: April 21, 2015Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Publication number: 20150104485Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.Type: ApplicationFiled: April 16, 2013Publication date: April 16, 2015Applicant: LUBRIZOL ADVANCED MATERIALS, INC.Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
-
Publication number: 20150105335Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.Type: ApplicationFiled: October 3, 2014Publication date: April 16, 2015Inventor: Richard Franklin
-
Publication number: 20150098990Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.Type: ApplicationFiled: October 8, 2014Publication date: April 9, 2015Inventors: Lawrence Chan, Hideto Kojima, Tomoya Terashima
-
Publication number: 20150098989Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.Type: ApplicationFiled: April 12, 2013Publication date: April 9, 2015Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
-
Patent number: 8999932Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.Type: GrantFiled: July 29, 2010Date of Patent: April 7, 2015Assignee: KAI Pharmaceuticals, Inc.Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
-
Publication number: 20150093463Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.Type: ApplicationFiled: October 14, 2014Publication date: April 2, 2015Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Patent number: 8987191Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: GrantFiled: June 21, 2013Date of Patent: March 24, 2015Assignee: Compugen Ltd.Inventors: Ronen Shemesh, Zurit Levine, Amir Toporik, Chen Hermesh, Yossef Kliger, Eyal Gofer, Assaf Wool, Dvir Dahary, Yossi Cohen
-
Publication number: 20150079179Abstract: The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided.Type: ApplicationFiled: September 15, 2014Publication date: March 19, 2015Inventor: Gary P. COOK
-
Publication number: 20150065424Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.Type: ApplicationFiled: November 17, 2014Publication date: March 5, 2015Applicant: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Publication number: 20150057236Abstract: Sirt5, a mitochondrial Sirtuin, has been identified herein as an efficient demalonylase and desuccinylase. Disclosed herein are assays to identify Sirt5 modulators based on this robust enzymatic activity. Sirt5-specific modulators can be used study the biological function of Sirt5 and to target Sirt5 activities in treating human diseases.Type: ApplicationFiled: July 7, 2011Publication date: February 26, 2015Applicant: CORNELL UNIVERSITYInventor: Hening Lin
-
Publication number: 20150056167Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: September 4, 2014Publication date: February 26, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Patent number: 8962571Abstract: A method for repairing DNA damage in human keratinocytes by applying to the keratinocytes a composition comprising at least one CLOCK or PER1 gene activator and at least one DNA repair enzyme.Type: GrantFiled: April 20, 2012Date of Patent: February 24, 2015Assignee: ELC ManagementInventors: Daniel H. Maes, Nadine A. Pernodet, Lenny Slutsky, Donald F. Collins, Kerri Goldgraben, Edward Pelle, James Timothy McCarthy
-
Patent number: 8962565Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1—X2—X3-Asp-Leu-Lys-Lys-X4—X5-(AA)p-R2, cosmetic or pharmaceutical compositions comprising at least one peptide compound of general formula (I) in a physiologically acceptable medium, and methods for cosmetic treatment of skin are disclosed. The peptide compounds of general formula (I) were demonstrated to be agents making it possible to influence the pigmentation of the skin and skin appendages, by ensuring optimal transfer of the melanosomes to the keratinocytes, so as to make the skin tone uniform owing to an effect on the SCF/c-Kit signaling pathway. The compounds, compositions, and methods treat or attenuate age-related pigmentation defects and the effects of photoaging on the skin.Type: GrantFiled: January 30, 2012Date of Patent: February 24, 2015Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20150051159Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: ApplicationFiled: October 27, 2014Publication date: February 19, 2015Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 8957013Abstract: The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4,-dinitrotoluene (DNT).Type: GrantFiled: October 13, 2009Date of Patent: February 17, 2015Assignee: The Regents of the University of CaliforniaInventors: Justyn W. Jaworski, Seung-Wuk Lee, Arunava Majumdar, Digvijay A. Raorane
-
Patent number: 8957185Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.Type: GrantFiled: February 24, 2012Date of Patent: February 17, 2015Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLCInventors: Donald W. Kufe, Surender Kharbanda
-
Patent number: 8957032Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.Type: GrantFiled: May 6, 2009Date of Patent: February 17, 2015Assignee: Alba Therapeutics CorporationInventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
-
Oligopeptide for treating liver fibrosis and/or treating hepatitis B and/or improving liver function
Patent number: 8957019Abstract: Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to the oligopeptide prepared according to the present invention to prepare various dosage forms. The oligopeptide has good efficacy in treating liver fibrosis and improving liver function.Type: GrantFiled: November 1, 2011Date of Patent: February 17, 2015Inventors: Haimin Lei, Qiang Li -
Patent number: 8951963Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate.Type: GrantFiled: March 27, 2013Date of Patent: February 10, 2015Assignee: Drexel UniversityInventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
-
Patent number: 8952128Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.Type: GrantFiled: October 31, 2013Date of Patent: February 10, 2015Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
-
Publication number: 20150037376Abstract: Methods and compositions for oral administration of melanocortin receptor agonist compounds are disclosed herein. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of sexual dysfunction, including male sexual dysfunction and female sexual dysfunction. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of metabolic syndrome, obesity and/or diabetes. In some embodiments, a pharmaceutical composition comprising a peptide-based melanocortin receptor agonist, a protease inhibitor, an absorption enhancer is administered orally.Type: ApplicationFiled: November 2, 2012Publication date: February 5, 2015Inventors: Gaurav Seth, Natan Bar-Chama
-
Patent number: 8946166Abstract: Peptides of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zs-R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, their preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases that are a consequence of muscle contraction.Type: GrantFiled: July 23, 2010Date of Patent: February 3, 2015Assignee: Lipotec, S.A.Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech, Gregorio Fernandez Ballester
-
Publication number: 20150031634Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.Type: ApplicationFiled: October 3, 2014Publication date: January 29, 2015Inventor: Richard Franklin